Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations

Summary Background Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post‐operative complications. Aim We sought to compare 30‐day postoperative infectious complication rate among vedolizumab‐treated Crohn's disease patients vs those who had received TNF α inhibitors...